BHVN vs LLY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BHVN and LLY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BHVN and LLY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, and obesity. It was created in 2022 when Pfizer acquired the original Biohaven's CGRP migraine business (including Nurtec ODT) for roughly $11.6 billion; the remaining non-CGRP pipeline was spun out into the current publicly traded Biohaven Ltd. Its programs include taldefgrobep alfa (a myostatin-activin pathway inhibitor being tested in obesity and spinal muscular atrophy), troriluzole (VYGLXIA, targeted at spinocerebellar ataxia), opakalim (BHV-7000, a Kv7 ion channel activator for focal epilepsy and depression), and MoDE and TRAP extracellular degraders such as BHV-1300 (Graves' disease) and BHV-1400 (IgA nephropathy).

Full BHVN guide

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BHVN drivers: Taldefgrobep obesity readout; Opakalim epilepsy and depression.
• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Biohaven is pre-major-revenue and posts large quarterly net losses, so it depends on repeated equity financing that dilutes existing shareholders. For LLY, lLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply.

Pick BHVN if you believe its drivers more; LLY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BHVN and LLY guides.

BHVN. Biohaven trades as a pipeline-value biotech rather than on earnings, with a market cap around $2.3 billion against minimal product revenue and heavy research spending. Q1 2026 saw the net loss narrow to about $130 million from roughly $222 million a year earlier as R&D was trimmed, and the company raised about $179 million through its at-the-market equity program, lifting shares outstanding to roughly 150 million. Cash of about $352 million relative to a nine-figure quarterly burn keeps financing and runway front of mind.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

Headline figures (approximate, JULY 2026): BHVN shows market cap ~$2.3B, share price ~$17, 52-week range ~$7.50 to ~$18.60, q1 2026 net loss ~$130M; LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify).

BHVN and LLY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BHVN and LLY exposure against your real portfolio. It is not an investment adviser.